| EN
We are rapidly transitioning to an innovation and R&D-driven pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today’s patients with medicines of the future” (让患者早日用上更有效药物). We have established three R&D centers in Nanjing, Shanghai and Boston, respectively. With the approval of the Ministry of Science and Technology, we have also established a national key laboratory of translational medicine and innovative pharmaceuticals (转化医学与创新药物国家重点实验室). We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China (中国创新力医药企业十强)” and “Top 100 Pharmaceutical Manufacturing Enterprises of China (中国制药工业百强)”.

Milestones

  • 1995

  • 2001

  • 2003

  • 2006

  • 2007

  • 2013

  • 2015

  • 2018

  • established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals

  • cquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, built our own research and development team

  • acquired the entire equity interest in Simcere Dongyuan, established postdoctoral research station (博士后科研工作站)

  • acquired a controlling interest in Shandong Simcere

  • became the first bio and chemical pharmaceutical company in China to be listed on the NYSE

  • completed the privatization

  • established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (转化医学与创新药物国家重点实验室) approved by the Ministry of Science and Technology

  • Shanghai R&D center established

  • established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
  • cquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, built our own research and development team
  • acquired the entire equity interest in Simcere Dongyuan, established postdoctoral research station (博士后科研工作站)
  • acquired a controlling interest in Shandong Simcere
  • became the first bio and chemical pharmaceutical company in China to be listed on the NYSE
  • completed the privatization
  • established the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (转化医学与创新药物国家重点实验室) approved by the Ministry of Science and Technology
  • Shanghai R&D center established

Management Team

Ren Jinsheng

Chairman of the Board and
Chief Executive Officer

Tang Renhong, PhD

Executive Director and
Co-Chief Executive Officer

Wan Yushan

Executive Director and
Chief Financial Officer

Bijoyesh Mookerjee, MD

Chief Medical Officer, Oncology

Zhou Gaobo

Chief Investment Officer

Tamas Oravecz, PhD

Senior Vice President,CSO of Simcere, U.S.

Andrew Zhu

Senior Vice President

Danny Chen, PhD

Senior Vice President

Kevin Oliver, PhD

Senior Vice President

Song Wenjie

Senior Vice President

Mission

Providing Today’s Patients with Medicines of the Future

Core values

Integrity
Excellence
Perseverance
Proactivity
Customer-First

Simcere CI

  • The name “Simcere” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
  • On the left side of our logo is Simcerer running against the wind, representing the spirit of unremitting endeavor and the encourage to pursue excellence.
  • The color green symbolizes life, health and vitality.